Company intelligence / Profile preview

Activaero

Gemünden*, Hessen, Germanypmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~50
Development stage: Phase 3

Overview

As of its acquisition by Vectura Group plc in March 2014, Activaero had seven clinical and several preclinical programs using its proprietary inhalation technology. Its lead program targeted severe asthma with the aim to reduce or eliminate oral corticosteroid use. The company generated €10.2 million revenue in FY2013 from device sales, licensing fees/milestones, and contract services[1].

Therapeutic areas: PulmonologyCardiovascularInfectious Diseases
Modalities: Inhaled therapeutics (via smart nebulisation technology)
Industry: Biotech

Drug pipeline

1 asset

budesonide

Phase 3

Indications: Severe asthma

Partnerships

Not specifically listed; outlicensing inhalation technologies to other pharmaceutical companies was part of business strategy post-acquisition by Vectura Group plc[1].

Beyond the preview

Go deeper on Activaero.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Activaero.

Explore the full profile